Analysts Set Embecta Corp. (NASDAQ:EMBC) Target Price at $19.00

Shares of Embecta Corp. (NASDAQ:EMBC) have received a consensus recommendation of “Hold” from the five brokerages that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $19.00.

Several brokerages have recently issued reports on EMBC. Zacks Research cut Embecta from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 7th. Wall Street Zen raised Embecta from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. BTIG Research reissued a “buy” rating and issued a $25.00 price objective on shares of Embecta in a report on Friday, September 5th. Mizuho dropped their target price on Embecta from $13.00 to $12.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 16th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Embecta in a report on Wednesday, October 8th.

Hedge Funds Weigh In On Embecta

A number of large investors have recently bought and sold shares of EMBC. Oppenheimer Asset Management Inc. raised its holdings in Embecta by 9.0% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 11,004 shares of the company’s stock worth $140,000 after purchasing an additional 907 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in Embecta in the 1st quarter worth about $154,000. Teacher Retirement System of Texas raised its holdings in Embecta by 64.3% in the 1st quarter. Teacher Retirement System of Texas now owns 91,525 shares of the company’s stock worth $1,167,000 after purchasing an additional 35,817 shares during the period. Principal Financial Group Inc. raised its holdings in Embecta by 3.4% in the 1st quarter. Principal Financial Group Inc. now owns 289,605 shares of the company’s stock worth $3,692,000 after purchasing an additional 9,601 shares during the period. Finally, Isthmus Partners LLC raised its holdings in shares of Embecta by 2.3% during the first quarter. Isthmus Partners LLC now owns 111,614 shares of the company’s stock valued at $1,423,000 after acquiring an additional 2,510 shares during the last quarter. Institutional investors and hedge funds own 93.83% of the company’s stock.

Embecta Price Performance

Shares of EMBC stock opened at $13.66 on Tuesday. The business has a fifty day moving average of $14.30 and a 200 day moving average of $12.22. The firm has a market capitalization of $798.97 million, a price-to-earnings ratio of 9.55, a price-to-earnings-growth ratio of 0.75 and a beta of 1.10. Embecta has a 1 year low of $9.20 and a 1 year high of $21.48.

Embecta (NASDAQ:EMBC) last issued its quarterly earnings data on Friday, August 8th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.35. The business had revenue of $295.50 million during the quarter, compared to analysts’ expectations of $278.15 million. Embecta had a negative return on equity of 23.40% and a net margin of 7.58%.The company’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.74 EPS. Embecta has set its FY 2025 guidance at 2.900-2.950 EPS. As a group, equities research analysts expect that Embecta will post 2.85 earnings per share for the current year.

Embecta Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, September 15th. Investors of record on Friday, August 29th were issued a $0.15 dividend. The ex-dividend date of this dividend was Friday, August 29th. This represents a $0.60 dividend on an annualized basis and a yield of 4.4%. Embecta’s dividend payout ratio is presently 41.96%.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.